A bioinformatics pipeline was developed to quantify fusion RNA expression.
Most cis-SAGe fusions are not unique to cancer samples.
D2HGDH-GAL3ST2 is rarely seen in normal samples, but frequently in prostate cancer.
D2HGDH-GAL3ST2 may play a role in prostate cancer progression.